Pipette dropping liquid into a petri dish
Pipette dropping liquid into a petri dish

SOHO 2022

OVERVIEW

28 - 01

Sep 2022

SOHO 2022

Houston, TX
Congress website

Annual meeting of global society of clinicians and scientists specializing in hematology.

PELABRESIB PRESENTATIONS

  • Poster

    Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs Ruxolitinib or Fedratinib Monotherapy in Patients With Intermediate- or High-risk Myelofibrosis

  • Poster

    Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease in Megakaryocytic Progenitors and Normalization of CD4+ T cells in Peripheral Blood

  • Poster

    BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis — JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib Preliminary Data From the MANIFEST Study

TAFASITAMAB PRESENTATIONS

  • Poster

    frontMIND: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

  • Poster

    Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

  • Poster

    L-MIND: A Safety and Efficacy Analysis of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Receiving Treatment For at Least 2 Years

  • Poster

    MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab + Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

  • Poster

    realMIND: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second-/Third-Line Therapy and Not Receiving a Stem Cell Transplant

  • Poster

    Subgroup Analysis in RE-MIND2, an Observational, Retrospective Cohort Study of Tafasitamab Plus Lenalidomide Versus Systemic Therapies in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

OTHER CONGRESSES

ASCO 2022

Annual meeting featuring presentations on the latest research in cancer care.

03/06 - 07/06 Chicago, IL
LEARN MORE

EHA 2022

European-based organization and congress promoting excellence in hematology.

09/06 - 12/06 Vienna, Austria
LEARN MORE

ASH 2022

World’s largest network supporting clinical and scientific hematology research.

10/12 - 13/12 New Orleans, LA
LEARN MORE

MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.